AIM: The objective is to develop a semi-mechanistic disease progression model for mild cognitive impairment (MCI) subjects. The model aims to describe the longitudinal progression of ADAS-cog scores from the Alzheimer's disease neuroimaging initiative trial that had data from 198 MCI subjects with cerebrospinal fluid (CSF) information who were followed for 3 years. METHOD: Various covariates were tested on disease progression parameters and these variables fell into six categories: imaging volumetrics, biochemical, genetic, demographic, cognitive tests and CSF biomarkers. RESULTS: CSF biomarkers were associated with both baseline disease score and disease progression rate in subjects with MCI. Baseline disease score was also correlated with atrophy measured using hippocampal volume. Progression rate was also predicted by executive functioning as measured by the Trail B-test. CONCLUSION: CSF biomarkers have the ability to discriminate MCI subjects into sub-populations that exhibit markedly different rates of disease progression on the ADAS-cog scale. These biomarkers can therefore be utilized for designing clinical trials enriched with subjects that carry the underlying disease pathology.
AIM: The objective is to develop a semi-mechanistic disease progression model for mild cognitive impairment (MCI) subjects. The model aims to describe the longitudinal progression of ADAS-cog scores from the Alzheimer's disease neuroimaging initiative trial that had data from 198 MCI subjects with cerebrospinal fluid (CSF) information who were followed for 3 years. METHOD: Various covariates were tested on disease progression parameters and these variables fell into six categories: imaging volumetrics, biochemical, genetic, demographic, cognitive tests and CSF biomarkers. RESULTS: CSF biomarkers were associated with both baseline disease score and disease progression rate in subjects with MCI. Baseline disease score was also correlated with atrophy measured using hippocampal volume. Progression rate was also predicted by executive functioning as measured by the Trail B-test. CONCLUSION: CSF biomarkers have the ability to discriminate MCI subjects into sub-populations that exhibit markedly different rates of disease progression on the ADAS-cog scale. These biomarkers can therefore be utilized for designing clinical trials enriched with subjects that carry the underlying disease pathology.
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Hugo Vanderstichele; Mirko Bibl; Sebastiaan Engelborghs; Nathalie Le Bastard; Piotr Lewczuk; Jose Luis Molinuevo; Lucilla Parnetti; Armand Perret-Liaudet; Leslie M Shaw; Charlotte Teunissen; Dirk Wouters; Kaj Blennow Journal: Alzheimers Dement Date: 2011-11-02 Impact factor: 21.566
Authors: Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow Journal: Nat Rev Drug Discov Date: 2010-07 Impact factor: 84.694
Authors: Barbara J Snider; Anne M Fagan; Catherine Roe; Aarti R Shah; Elizabeth A Grant; Chengjie Xiong; John C Morris; David M Holtzman Journal: Arch Neurol Date: 2009-05
Authors: Niklas Mattsson; Ulf Andreasson; Staffan Persson; Hiroyuki Arai; Sat Dev Batish; Sergio Bernardini; Luisella Bocchio-Chiavetto; Marinus A Blankenstein; Maria C Carrillo; Sonia Chalbot; Els Coart; Davide Chiasserini; Neal Cutler; Gunilla Dahlfors; Stefan Duller; Anne M Fagan; Orestes Forlenza; Giovanni B Frisoni; Douglas Galasko; Daniela Galimberti; Harald Hampel; Aase Handberg; Michael T Heneka; Adrianna Z Herskovits; Sanna-Kaisa Herukka; David M Holtzman; Christian Humpel; Bradley T Hyman; Khalid Iqbal; Mathias Jucker; Stephan A Kaeser; Elmar Kaiser; Elisabeth Kapaki; Daniel Kidd; Peter Klivenyi; Cindy S Knudsen; Markus P Kummer; James Lui; Albert Lladó; Piotr Lewczuk; Qiao-Xin Li; Ralph Martins; Colin Masters; John McAuliffe; Marc Mercken; Abhay Moghekar; José Luis Molinuevo; Thomas J Montine; William Nowatzke; Richard O'Brien; Markus Otto; George P Paraskevas; Lucilla Parnetti; Ronald C Petersen; David Prvulovic; Herman P M de Reus; Robert A Rissman; Elio Scarpini; Alessandro Stefani; Hilkka Soininen; Johannes Schröder; Leslie M Shaw; Anders Skinningsrud; Brith Skrogstad; Annette Spreer; Leda Talib; Charlotte Teunissen; John Q Trojanowski; Hayrettin Tumani; Robert M Umek; Bianca Van Broeck; Hugo Vanderstichele; Laszlo Vecsei; Marcel M Verbeek; Manfred Windisch; Jing Zhang; Henrik Zetterberg; Kaj Blennow Journal: Alzheimers Dement Date: 2011-07 Impact factor: 21.566
Authors: Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon Journal: Lancet Neurol Date: 2006-03 Impact factor: 44.182
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2015-06 Impact factor: 21.566
Authors: Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin Journal: Cochrane Database Syst Rev Date: 2017-03-22
Authors: Daniel S Spellman; Kristin R Wildsmith; Lee A Honigberg; Marianne Tuefferd; David Baker; Nandini Raghavan; Angus C Nairn; Pascal Croteau; Michael Schirm; Rene Allard; Julie Lamontagne; Daniel Chelsky; Steven Hoffmann; William Z Potter Journal: Proteomics Clin Appl Date: 2015-04-24 Impact factor: 3.494